乳腺癌放疗皮肤反应:患者报告结局与临床医生评估的前瞻性比较
该前瞻性研究纳入777例术后放疗乳腺癌患者,在基线、放疗期间每周及随访1–3个月时同步采集患者报告结局(PRO)与临床医生报告结局(CRO)的皮肤症状评估。结果显示所有皮肤症状条目均被临床医生显著低估(p<0.0001),一致性低至中等(C-statistic 0.58–0.70,一致率29–50%)。结论认为仅靠CRO不足以评估放射性皮炎(RD),需开发兼顾患者与医生成分的新工具。
要点
- 临床医生对所有皮肤症状条目的报告显著低于患者(p<0.0001)。
- PRO与CRO一致性低至中等,C-statistic 0.58–0.70,一致率29–50%。
- 65.1%患者按机构指南预防性使用保湿霜。
核心结论
- 乳腺癌RD评估中PRO与CRO存在显著差异,仅用CRO不足以捕捉对患者生活质量的影响。
- 研究支持开发同时包含患者与临床医生成分的RD症状评估新工具。
研究设计与样本
- 前瞻性分析,纳入2018年2月至2020年9月接受术后放疗的乳腺癌患者777例。
- 在基线、放疗期间每周及随访1–3个月时由患者与临床医生完成皮肤症状评估,并收集患者使用的皮肤治疗。
- 采用一致率与逻辑回归的一致性指数(C-statistic)评价每个PRO与CRO的一致性。
主要发现
- 所有皮肤症状评估条目均被临床医生较患者显著低估(p<0.0001)。
- PRO与CRO一致性为低至中等(C-statistic范围0.58–0.70;一致率范围29–50%)。
- 多数患者按机构指南预防性使用保湿霜(65.1%)。
关键数值与推荐
- PRO与CRO一致性指标:C-statistic范围0.58–0.70,一致率范围29–50%。
- 所有皮肤症状条目临床医生低估的显著性水平:p<0.0001。
- 预防性使用保湿霜的患者比例:65.1%。
临床怎么用
- 乳腺癌术后放疗的RD评估应同时采集患者报告结局,避免仅依赖临床医生评估。
- 关注患者预防性使用保湿霜等皮肤护理行为,并将其纳入症状管理记录。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Breast cancer patients frequently develop radiation dermatitis (RD) when undergoing post-operative radiation therapy (RT). Traditional RD assessment methods measure clinician-reported outcomes (CROs), but patient-reported outcomes (PROs) have gained recent popularity. The purpose of this prospective analysis was to compare PROs with CROs of breast RD. MATERIALS AND METHODS: Demographic and treatment characteristics were prospectively collected for patients receiving post-operative RT between February 2018 to September 2020. Patients and clinicians completed a skin symptom assessment at baseline, weekly during RT, and at a one- to three-month follow-up visit. Skin treatments used by patients were collected. Concordance between each PRO and CRO was determined using percent concordance and concordance index (C-statistic) by logistic regression analysis. RESULTS: A total of 777 patients were included in the present study. All skin symptom assessment items were significantly underreported by clinicians in comparison to patients (p < 0.0001), with a low to moderate level of concordance (C-statistic range: 0.58-0.70; percent concordance range: 29-50%). The majority of patients used moisturizing creams as a prophylactic measure (65.1%), as per institutional guidelines. CONCLUSION: There were significant discrepancies between PROs and CROs when assessing breast RD. CROs alone are insufficient in measuring RD as they fail to capture the impact on patient quality of life. The study findings highlight the need for improved RD symptom assessment and support the development of a new tool with both patient and clinician components.
引用
- Behroozian T, Milton L, Zhang L, et al. How do patient-reported outcomes compare with clinician assessments? A prospective study of radiation dermatitis in breast cancer. Radiother Oncol. 2021. PMID: 33771577. doi:10.1016/j.radonc.2021.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。